SOLID-TIMI 52 was a randomized, double-blind, placebo-controlled trial to assess the efficacy of darapladib, a novel Lp-PLA2 inhibitor, when added to standard of care in high-risk patients stabilized after ACS.
MAIN RESULTS:
Rivaroxaban in patients with a recent acute coronary syndrome

PRESENTATIONS
TIMI 52 Slides
SOLID Ceramides (Gencer AHA 2019)
A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients with Cardiometabolic Disease (Patel, AHA 2020)
PUBLICATIONS
Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome
Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome
Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials
Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events